Last reviewed · How we verify
RS1 AAV Vector
At a glance
| Generic name | RS1 AAV Vector |
|---|---|
| Sponsor | VegaVect, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis (EARLY_PHASE1)
- Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis (PHASE1, PHASE2)
- Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RS1 AAV Vector CI brief — competitive landscape report
- RS1 AAV Vector updates RSS · CI watch RSS
- VegaVect, Inc. portfolio CI